secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0001193125-24-262541
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm appoints Kristin Abate as VP, Chief Accounting Officer, effective Nov 20, 2024
--------------------------------------------------------------------------------

- Kristin Abate appointed Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024.
- She continues as interim principal financial officer; designated as principal accounting officer.
- Abate has been with Karyopharm since July 2019, most recently as VP Accounting, Corporate Controller, Assistant Treasurer.
- Prior to Karyopharm, she spent 12 years at PricewaterhouseCoopers LLP; CPA with MS in Accountancy from Boston College.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524262541/0001193125-24-262541-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524262541/d858096d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-262541

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer